The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.
Saved in:
| Title: | The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. |
|---|---|
| Authors: | Stocker K; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.; Chair of Cognitive Science, Department of Humanities, Social and Political Sciences, ETH Swiss Federal Institute of Technology Zurich, Switzerland.; Department of Psychology, University of Zurich, Switzerland.; Faculty of Psychology, UniDistance Suisse, Brig, Switzerland., Hartmann M; Faculty of Psychology, UniDistance Suisse, Brig, Switzerland., Schmid Y; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Vogt SB; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Becker AM; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Ley L; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Straumann I; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Arikci D; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Klaiber A; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Erne L; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Vizeli P; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Holze F; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland., Liechti ME; Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland. |
| Source: | Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2026 May; Vol. 40 (5), pp. 850-862. Date of Electronic Publication: 2025 Dec 26. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Sage Publications Country of Publication: United States NLM ID: 8907828 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1461-7285 (Electronic) Linking ISSN: 02698811 NLM ISO Abbreviation: J Psychopharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1461-7285 |
|---|---|
| DOI: | 10.1177/02698811251397328 |
